DOCSLIB.ORG

A Pre-Clinical Investigation of the Anti-Cancer Effects of the Frankincense Constituent AKBA on Ovarian Cancer Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Pre-Clinical Investigation of the Anti-Cancer Effects of the Frankincense Constituent AKBA on Ovarian Cancer Cells A Pre-Clinical Investigation of the Anti-Cancer Effects of the Frankincense Constituent AKBA on Ovarian Cancer Cells Thesis submitted for the degree of Doctor of Philosophy at the University of Leicester by Kamla Khalfan Said Al-Salmani BSc (Hons), MSc Department of Cancer Studies University of Leicester 2016 Abstract A pre-clinical investigation of the anti-cancer effects of the frankincense constituent AKBA on ovarian cancer cells This study examines the biologically active component of frankincense, 3-O-acetyl-11- keto-β-boswellic acid (AKBA), in ovarian cancer cells to evaluate its potential cytotoxicity towards high grade serous ovarian cancer and its potential ability to address the cancer’s known resistance to cisplatin. Ovarian cancer causes significant mortality, the five-year survival rate being very low compared to other cancers as most of the cases are diagnosed late, typically at stages IIIa- IIIc and IV. Most of these cases relapse and develop resistance to first line chemotherapy; therefore, new strategies are urgently needed to overcome resistance. Extracts from Boswellia sp., used for centuries as herbal medicine in Asia, have known anti- inflammatory properties and anti-cancer potential alone or in combination with other chemotherapies. The active ingredients of Boswellia sp., boswellic acids, have many effects on various cancer cells including induction of apoptosis. In this study, several approaches and analyses were performed in examining the effect of AKBA on four ovarian cancer cell lines, including a cisplatin resistant line. These investigations included analysis of cell proliferation and viability, cell cycle distribution, apoptosis, DNA damage formation, production of reactive oxygen species and gene expression. The results obtained from this work suggest that AKBA induces apoptosis in ovarian cancer cell lines either directly through extrinsic and intrinsic pathways, or indirectly by affecting other cellular mechanisms such as inhibiting cell proliferation/viability, inducing DNA damage and decreasing production of reactive oxygen species. Furthermore, AKBA exposure alters the expression of multiple genes, potentially impacting on several cellular processes. The key findings of this project are that AKBA is cytotoxic to ovarian cancer cells, at pharmacologically achievable concentrations. AKBA exposure also induces multiple gene expression changes that would impact on many different biological pathways in ovarian cancer cells including genes related to DNA damage and repair, cell cycle, cell metabolism, and cell adhesion and metastasis. Consequently, AKBA may form the basis of a novel anticancer treatment for ovarian cancer potentially alongside conventional therapy. I Acknowledgements Firstly, I would like to express my thanks to the University of Leicester for accepting this project proposal for my PhD. I would like to express my gratitude to my supervisors, Prof George DD Jones, Dr Mark Evans and Dr Esther Moss for their guidance, advice, support, and encouragement during this project. I also thank Dr Raj Patel for his advice and support during this project and I thank Dr Salvador Macip for his help in using the flow cytometry machine. I would like to thank my co-supervisor Dr Ikram Burney from Sultan Qaboos University for all his support throughout the project time. My thanks also extends to our departmental postgraduate tutor Dr Don Jones for his support, encouragement and overseeing of this project and also to Dr Nicolas Sylvius of Nucleus Genomics, Genetics Department for running the microarray samples and for his assistance in analysing the results. I would like to thank all the people in other laboratories who gave me help and who allowed me to use their facilities. I am grateful to the Ministry of Health, Ministry of Higher Education and my colleagues and staff at the National genetic centre in Oman. Lastly, huge thanks to my family, words cannot express how grateful I am to my parents, my in-laws for their support and encouragement. Finally, I would like to acknowledge my deepest gratitude to my beloved husband and my children. II List of contents Abstract ....................................................................................................................... I Acknowledgements ..................................................................................................... II List of table’s and figures ........................................................................................ VII List of Equations ........................................................................................................ X List of Abbreviations: ............................................................................................... XI Chapter one ................................................................................................................... 15 Thesis Introduction ....................................................................................................... 15 1.1 Frankincense ....................................................................................................... 16 1.1.1 Boswellic acids .......................................................................................... 18 1.1.2 Medicinal uses of Frankincense ................................................................. 20 1.1.3 Acetyl-11-keto-beta-boswellic acid (AKBA): ........................................... 22 1.1.4 Cytotoxic properties of Boswellic acid and mainly AKBA: ..................... 23 1.1.5 Cell line studies and cytotoxicity ............................................................... 23 1.1.6 Metabolic activity of Boswellic acids and AKBA ..................................... 30 1.2 Ovarian Cancer ................................................................................................... 31 1.2.1 Ovarian cancer subtype .............................................................................. 33 1.2.2 Aetiology and Pathophysiology of Ovarian Cancer .................................. 33 1.2.3 Current treatment of ovarian cancer. ......................................................... 35 1.2.4 Ovarian cancer cell-lines for in vitro studies ............................................. 37 1.2.4.1 A2780 and A2780cis .............................................................................. 37 1.2.4.2 OVCAR-4 ............................................................................................... 38 1.2.4.3 UWB1.289 .............................................................................................. 39 1.3 DNA damage & repair ........................................................................................ 40 1.4 The Cell Cycle. ................................................................................................... 41 1.5 Aims and objectives ............................................................................................ 42 1.5.1 Hypothesis ................................................................................................. 43 III Chapter 2 ....................................................................................................................... 44 Materials and Methods ................................................................................................. 44 2. Materials and Methods: ........................................................................................ 45 2.1 Cell-lines for in vitro studies ........................................................................ 45 2.2 Cell lines used in this research ...................................................................... 45 2.4 Summary of the techniques/approach ........................................................... 46 2.5 Cell culture medium and supplements .......................................................... 46 2.6 Chemicals and Reagents ............................................................................... 46 2.7 Kits and antibodies ........................................................................................ 47 2.8 Preparation of buffers and working reagents ................................................ 48 2.8.1 The test compound AKBA ........................................................................ 49 2.9 Cell culture .................................................................................................... 49 2.10 Cell Culture: ................................................................................................ 50 2.11 Methods ...................................................................................................... 51 2.11.9 Gene expression ....................................................................................... 66 2.11.10 Quantitative-PCR (Q-PCR) ................................................................... 70 2.11.11 Statistical Analysis ................................................................................. 73 Chapter 3 ....................................................................................................................... 74 Investigations for the ability of AKBA to address cisplatin resistance in ovarian cancer cell lines .............................................................................................................. 74 3.1 Introduction ......................................................................................................... 75 3.1.1 Ovarian Cancer: ........................................................................................
Load more

Recommended publications
  • Immunolocalization of Cannabinoid Receptor Type 1 and CB2 Cannabinoid Receptors, and Transient Receptor Potential Vanilloid Channels in Pterygium
    MOLECULAR MEDICINE REPORTS 16: 5285-5293, 2017 Immunolocalization of cannabinoid receptor type 1 and CB2 cannabinoid receptors, and transient receptor potential vanilloid channels in pterygium MARTHA ASSIMAKOPOULOU1, DIONYSIOS PAGOULATOS1, PINELOPI NTERMA1 and NIKOLAOS PHARMAKAKIS2 Departments of 1Anatomy, Histology and Embryology, and 2Ophthalmology, School of Medicine, University of Patras, GR-26504 Rio, Greece Received July 27, 2016; Accepted January 19, 2017 DOI: 10.3892/mmr.2017.7246 Abstract. Cannabinoids, as multi-target mediators, acti- CB2 (P>0.05). Additionally, CB1 and CB2 were significantly vate cannabinoid receptors and transient receptor potential highly expressed in primary pterygia (P=0.01), compared with vanilloid (TRPV) channels. There is evidence to support a recurrent pterygia. Furthermore, CB1 expression levels were functional interaction of cannabinoid receptors and TRPV significantly correlated with CB2 expression levels in primary channels when they are coexpressed. Human conjunctiva pterygia (P=0.005), but not in recurrent pterygia (P>0.05). demonstrates widespread cannabinoid receptor type 1 (CB1), No significant difference was detected for all TRPV channel CB2 and TRPV channel localization. The aim of the present expression levels between pterygium (primary or recurrent) study was to investigate the expression profile for cannabinoid and conjunctival tissues (P>0.05). A significant correlation receptors (CB1 and CB2) and TRPV channels in pterygium, between the TRPV1 and TRPV3 expression levels (P<0.001) an ocular surface lesion originating from the conjunctiva. was detected independently of pterygium recurrence. Finally, Semi‑serial paraffin‑embedded sections from primary and TRPV channel expression was identified to be significantly recurrent pterygium samples were immunohistochemically higher than the expression level of cannabinoid receptors in the examined with the use of specific antibodies.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • PCHHAX Comparative Phytochemical and Pharmacological Study Of
    Available online a t www.derpharma chemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(1):67-83 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Comparative phytochemical and pharmacological study of antitussive and antimicrobial effects of boswellia and thyme essential oils Kamilia F. Taha 1, Mona H. Hetta 2, Walid I. Bakeer 3, Nemat A. Z. Yassin 4, Bassant M. M. Ibrahim 4 and Marwa E. S. Hassan 1 1Phytochemistry Department, Applied Research Center of Medicinal Plants, National Organization for Drug Control and Research (NODCAR), Egypt 2Pharmacognosy Department, Fayoum University, Fayoum, Egypt 3Microbiology Department, Beni -Suef University, Egypt 4Pharmacology Department, National Research Centre, Dokki, Giza, Egypt _____________________________________________________________________________________________ ABSTRACT Essential oils are commonly used in herbal cough mixtures as antitussive and antimicrobial preparations, for instance Thyme oil is used in many cough preparations in the Egyptian market and also Boswellia oil is traditionally used as an antitussive. The aim of this study is to compare the antitussive and antimicrobial activity of essential oils of Boswellia carterii and Thymus vulgaris referring to their chemical components which were studied by using different methods of analysis (UV, HPTLC, HPLC, GC and GC/MS). HPLC technique was used for the first time for analysis of Boswellia oil. Results showed that the principal component of Boswellia oil was octyl acetate (35.1%), while the major constituent of Thyme oil was thymol (51%). Both oils were effective as antitussives but Thyme oil was more efficient (89.3%) than Boswellia oil (59%) and also as antimicrobial. It could be concluded that Thyme and Boswellia oils are effective as antitussives but less with Boswellia oil which could serve as an adjuvant in herbal cough mixture but cannot replace Thyme oil.
    [Show full text]
  • Transient Receptor Potential Channels and Metabolism
    Molecules and Cells Minireview Transient Receptor Potential Channels and Metabolism Subash Dhakal and Youngseok Lee* Department of Bio and Fermentation Convergence Technology, Kookmin University, BK21 PLUS Project, Seoul 02707, Korea *Correspondence: [email protected] https://doi.org/10.14348/molcells.2019.0007 www.molcells.org Transient receptor potential (TRP) channels are nonselective Montell, 2007). These cationic channels were first charac- cationic channels, conserved among flies to humans. Most terized in the vinegar fly, Drosophila melanogaster. While TRP channels have well known functions in chemosensation, a visual mechanism using forward genetic screening was thermosensation, and mechanosensation. In addition to being studied, a mutant fly showed a transient response to being sensing environmental changes, many TRP channels constant light instead of the continuous electroretinogram are also internal sensors that help maintain homeostasis. response recorded in the wild type (Cosens and Manning, Recent improvements to analytical methods for genomics 1969). Therefore, the mutant was named as transient recep- and metabolomics allow us to investigate these channels tor potential (trp). In the beginning, researchers had spent in both mutant animals and humans. In this review, we two decades discovering the trp locus with the germ-line discuss three aspects of TRP channels, which are their role transformation of the genomic region (Montell and Rubin, in metabolism, their functional characteristics, and their 1989). Using a detailed structural permeation property anal- role in metabolic syndrome. First, we introduce each TRP ysis in light-induced current, the TRP channel was confirmed channel superfamily and their particular roles in metabolism. as a six transmembrane domain protein, bearing a structural Second, we provide evidence for which metabolites TRP resemblance to a calcium-permeable cation channel (Mon- channels affect, such as lipids or glucose.
    [Show full text]
  • Full-Text (PDF)
    Review ARticle دوره هفتم، شماره سوم، تابستان 1398 دوره هفتم، شماره سوم، تابستان 1398 Review on the Third International Neuroinflammation Congress and Student Fes tival of Neuroscience in Mashhad University of Medical Sciences 1 2 1, 3* Sayed Mos tafa Modarres Mousavi , Sajad Sahab Negah , Ali Gorji 1Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran 2Department of Neuroscience, Mashhad University of Medical Sciences, Mashhad, Iran 3 Epilepsy Research Center, Department of Neurology and Neurosurgery, Wes tfälische Wilhelms-Universität Müns ter, Müns ter, Germany Article Info: Received: 11 June 2019 Revised: 12 June 2019 Accepted: 13 June 2019 ABSTRACT Introduction: Neuroinflammation congress was the third in a series of annual events aimed to facilitate the inves tigative and analytical discussions on a range of neuroinflammatory diseases. The neuroinflammation congress focused on various neuroinflammatory disorders, including multiple sclerosis, brain tumors, epilepsy, and neurodegenerative diseases. The conference was held in June 11-13, 2019 and organized by Mashhad University of Medical Sciences and Muns ter University, which aimed to shed light on the causes of neuroinflammatory diseases and uncover new treatment pathways. Conclusion: Through a comprehensive scientific program with a broad basic and clinical aspects, we discussed the basic aspects of neuroinflammation and neurodegeneration up to the s tate-of-the-art treatments. In this congress, 334 scientific topics were presented and discussed. Key words:
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Terpene Screening Library Item No. 9003370 • Batch No. 0611615 Panels are routinely re-evaluated to include new catalog introductions as the research evolves. Page 1 of 4 Plate Well Contents Item Number 1 A1 Unused 1 A2 Ursolic Acid 10072 1 A3 Forskolin 11018 1 A4 Betulin 11041 1 A5 Lupeol 11215 1 A6 Paxilline 11345 1 A7 β-acetyl-Boswellic Acid 11674 1 A8 Andrographolide 11679 1 A9 Bakuchiol 11684 1 A10 Betulinic Acid 11686 1 A11 β-Elemonic Acid 11712 1 A12 Unused 1 B1 Unused 1 B2 Oleanolic Acid 11726 1 B3 Neoandrographolide 11742 1 B4 Asiatic Acid 11818 1 B5 Madecassic Acid 11854 1 B6 Cafestol 13999 1 B7 Ingenol 14031 1 B8 Bilobalide 14272 1 B9 (−)-Huperzine A 14620 1 B10 Ginkgolide B 14636 1 B11 Cucurbitacin B 14820 1 B12 Unused 1 C1 Unused 1 C2 Cucurbitacin E 14821 1 C3 Polygodial 14979 1 C4 Zerumbone 15400 1 C5 Ingenol-3-angelate 16207 1 C6 Ferutinin 16554 1 C7 Limonin 16932 1 C8 Phytol 17401 1 C9 Dehydrocostus lactone 18485 1 C10 β-Elemene 19641 1 C11 Juvenile Hormone III 19646 1 C12 Unused WARNING CAYMAN CHEMICAL THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. 1180 EAST ELLSWORTH RD SAFETY DATA ANN ARBOR, MI 48108 · USA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0038576A1 Timokhina Et Al
    US 20150.038576A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0038576A1 Timokhina et al. (43) Pub. Date: Feb. 5, 2015 (54) COMPOSITIONS AND THEIR USE FOR A24F 47/00 (2006.01) SMOKING CESSATION AND OTHER A63L/2 (2006.01) TREATMENTS A63L/II (2006.01) (71) Applicant: SENTIENS, LLC, Charlotte, NC (US) A6M I5/00 (2006.01) A63L/25 (2006.01) (72) Inventors: Inna S. Timokhina, Potomac, MD (US); A63L/343 (2006.01) Reid von Borstel, Potomac, MD (US); (52) U.S. Cl DennisMSG Tan, Weddington,NEW, NC 'S(US): CPCAV e. we............... A24B 15/16 (2013.01); A61 K3I/125 s s (2013.01); A61 K3I/05 (2013.01); A61 K (73) Assignee: SENTIENS, LLC, Charlotte, NC (US) 3 1/343 (2013.01); A61 K31/12 (2013.01); A6 IK3I/II (2013.01); A61M 15/009 (21) Appl. No.: 14/449,533 (2013.01); A24F 47/008 (2013.01) USPC ........... 514/470; 13 1/270; 13 1/273: 514/692; (22) Filed: Aug. 1, 2014 514/731: 514/678; 514/701: 128/200.14; 128/202.21 Related U.S. Application Data (60) Provisional application No. 61/861,865, filed on Aug. 2, 2013. (57) ABSTRACT Publication Classification A composition includes a liquid. The liquid aerosolizes for (51) Int. Cl. delivery to a user by an airway. The liquid includes an agent A24B 15/16 (2006.01) that activates a TRPV3 channel. The agent includes a terpe A6 IK3I/05 (2006.01) noid compound. Patent Application Publication Feb. 5, 2015 US 2015/0038576 A1 covC s US 2015/0038576 A1 Feb.
    [Show full text]
  • Camphor Elicits Up-Regulation of Hepatic and Pulmonary Pro
    Pathophysiology 26 (2019) 305–313 Contents lists available at ScienceDirect Pathophysiology jo urnal homepage: www.elsevier.com/locate/pathophys Camphor elicits up-regulation of hepatic and pulmonary pro-inflammatory cytokines and chemokines via activation of NF-kB in rats a,∗ b a a Oluwatobi T. Somade , Babajide O. Ajayi , Nurudeen O. Tajudeen , Eniola M. Atunlute , a a Adewale S. James , Samuel A. Kehinde a Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria b Department of Biochemistry, Bowen University, Iwo, Nigeria a r t i c l e i n f o a b s t r a c t Article history: Consumption of camphor infusions is widely used as an aphrodisiac in preparation for sexual intercourse, Received 10 April 2019 to boost performance. There is dearth of information associating or relating its consumption to liver or Received in revised form 8 May 2019 lung inflammation. Therefore, we investigated the effect of various doses of camphor in an acute study, Accepted 28 July 2019 on hepatic and pulmonary levels of some pro-inflammatory cytokines and chemokines in male wistar rats. Following administration, 2000 and 4000 mg/kg body weight camphor significantly increase liver Keywords: and lung levels of tumor necrosis factor alpha (TNF-␣), interleukin 1 beta (IL-1␤) and interleukin 6 (IL-6) Camphor in a dose dependent manner compared with control, while interleukin 10 (IL-10) levels were significantly Chemokines Cytokines increased only by 1000 and 4000 mg/kg body weight camphor in liver and lung respectively, compared Hepatic with control. Also compared with control, camphor administration resulted in a significant increase in the Pro-inflammation expressions of hepatic and pulmonary nuclear factor kappa B (NFkB), cyclooxygenase 2 (COX-2), regulated Pulmonary upon activation normal T cell expressed and secreted (RANTES) or CCL5, and monocyte chemo-attractant protein 1 (MCP-1) in a dose dependent manner.
    [Show full text]
  • TRPV3 in Drug Development
    pharmaceuticals Review TRPV3 in Drug Development Lisa M. Broad 1,*, Adrian J. Mogg 1, Elizabeth Eberle 2, Marcia Tolley 2, Dominic L. Li 3 and Kelly L. Knopp 3 1 Lilly Research Centre, Eli Lilly and Company Ltd., Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK; [email protected] 2 Covance Greenfield Laboratories, Greenfield, Indianapolis, IN 46140, USA; [email protected] (E.E.); [email protected] (M.T.) 3 Lilly Research Laboratories, Eli Lilly and Company Inc., Indianapolis, IN 46285, USA; [email protected] (D.L.L.); [email protected] (K.L.K.) * Correspondance: [email protected]; Tel.: +44-1276-483-016 Academic Editors: Arpad Szallasi and Susan M. Huang Received: 1 July 2016; Accepted: 31 August 2016; Published: 9 September 2016 Abstract: Transient receptor potential vanilloid 3 (TRPV3) is a member of the TRP (Transient Receptor Potential) super-family. It is a relatively underexplored member of the thermo-TRP sub-family (Figure1), however, genetic mutations and use of gene knock-outs and selective pharmacological tools are helping to provide insights into its role and therapeutic potential. TRPV3 is highly expressed in skin, where it is implicated in skin physiology and pathophysiology, thermo-sensing and nociception. Gain of function TRPV3 mutations in rodent and man have enabled the role of TRPV3 in skin health and disease to be particularly well defined. Pre-clinical studies provide some rationale to support development of TRPV3 antagonists for therapeutic application for the treatment of inflammatory skin conditions, itch and pain. However, to date, only one compound directed towards block of the TRPV3 receptor (GRC15300) has progressed into clinical trials.
    [Show full text]
  • Method Parameters' Impact on Mortality and Variability in Mouse Stroke Experiments: a Meta-Analysis
    www.nature.com/scientificreports OPEN Method parameters’ impact on mortality and variability in mouse stroke experiments: a meta- Received: 27 October 2015 Accepted: 13 January 2016 analysis Published: 15 February 2016 Edvin Ingberg1, Hua Dock1, Elvar Theodorsson1, Annette Theodorsson1,2 & Jakob O Ström1,3,4 Although hundreds of promising substances have been tested in clinical trials, thrombolysis currently remains the only specific pharmacological treatment for ischemic stroke. Poor quality, e.g. low statistical power, in the preclinical studies has been suggested to play an important role in these failures. Therefore, it would be attractive to use animal models optimized to minimize unnecessary mortality and outcome variability, or at least to be able to power studies more exactly by predicting variability and mortality given a certain experimental setup. The possible combinations of methodological parameters are innumerous, and an experimental comparison of them all is therefore not feasible. As an alternative approach, we extracted data from 334 experimental mouse stroke articles and, using a hypothesis-driven meta-analysis, investigated the method parameters’ impact on infarct size variability and mortality. The use of Swiss and C57BL6 mice as well as permanent occlusion of the middle cerebral artery rendered the lowest variability of the infarct size while the emboli methods increased variability. The use of Swiss mice increased mortality. Our study offers guidance for researchers striving to optimize mouse stroke models. Stroke is amongst the most common causes of death and disability worldwide1. Major advances have been made in the understanding of the pathophysiology of stroke and in vitro and animal experiments have suggested numerous substances as promising candidates for treatment of the disease2,3.
    [Show full text]
  • Neuropsychiatric Implications of Transient Receptor Potential Vanilloid (TRPV) Channels in the Reward System T
    Neurochemistry International 131 (2019) 104545 Contents lists available at ScienceDirect Neurochemistry International journal homepage: www.elsevier.com/locate/neuint Neuropsychiatric implications of transient receptor potential vanilloid (TRPV) channels in the reward system T ∗∗ ∗ Raghunath Singha, Yashika Bansala, Ishwar Parharb, Anurag Kuhada, , Tomoko Sogab, a Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India b Brain Research Institute Monash Sunway (BRIMS), Jeffrey Cheah School of Medicine and Health Science, Monash University Malaysia, Bandar Sunway, 47500, Malaysia ARTICLE INFO ABSTRACT Keywords: Neuropsychiatric disorders (NPDs) exert a devastating impact on an individual's personal and social well-being, TRPV channels encompassing various conditions and brain anomalies that influence affect, cognition, and behavior. Because the Addiction pathophysiology of NPDs is multifactorial, the precise mechanisms underlying the development of such disorders Food reward remain unclear, representing a unique challenge in current neuropsychopharmacotherapy. Transient receptor Opioids potential vanilloid (TRPV) type channels are a family of ligand-gated ion channels that mainly include sensory Alcohol receptors that respond to thermal, mechanical and chemical stimuli. TRPV channels are abundantly present in Cannabinoids dopaminergic neurons, thus playing a pivotal role in the modulation of the reward system and in pathophy- siology of diseases such as stress, anxiety, depression, schizophrenia, neurodegenerative disorders and substance abuse/addiction. Recent evidence has highlighted TRPV channels as potential targets for understanding mod- ulation of the reward system and various forms of addiction (opioids, cocaine, amphetamines, alcohol, nicotine, cannabis). In this review, we discuss the distribution, physiological roles, ligands and therapeutic importance of TRPV channels with regard to NPDs and addiction biology.
    [Show full text]
  • Contribution of Essential Oils to the Fight Against Microbial Biofilms—A
    processes Review Contribution of Essential Oils to the Fight against Microbial Biofilms—A Review 1, 1 2 3 4 Diana Camelia Nut, ă *, Carmen Limban , Cornel Chirit, ă , Mariana Carmen Chifiriuc , Teodora Costea , 5 5 5 Petre Ionit, ă , Ioana Nicolau and Irina Zarafu 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, TraianVuia no.6, 020956 Bucharest, Romania; [email protected] 2 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, TraianVuia no.6, 020956 Bucharest, Romania; [email protected] 3 Department of Microbiology, Faculty of Biology, Universtity of Bucharest, AleeaPortocalelor no.1-3, 060101 Bucharest, Romania; [email protected] 4 Department of Pharmacognosy, Phytochemistry, Phytotherapy, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, TraianVuia no.6, 020956 Bucharest, Romania; [email protected] 5 Department of Organic Chemistry, Biochemistry and Catalysis, Faculty of Chemistry, University of Bucharest, Regina Elisabeta no.4-12, 030018 Bucharest, Romania; [email protected] (P.I.); [email protected] (I.N.); [email protected] (I.Z.) * Correspondence: [email protected] Abstract: The increasing clinical use of artificial medical devices raises the issue of microbial con- tamination, which is a risk factor for the occurrence of biofilm-associated infections. A huge amount of scientific data highlights the promising potential of essential oils (EOs) to be used for the de- velopment of novel antibiofilm strategies. We aimed to review the relevant literature indexed in Citation: Nut˘a,D.C.; Limban, C.; , PubMed and Embase and to identify the recent directions in the field of EOs, as a new modality to Chirit, ˘a,C.; Chifiriuc, M.C.; Costea, T.; eradicate microbial biofilms.
    [Show full text]